Last reviewed · How we verify

NCT06261216

Association Between Lifetime Physical Activity and Exercise and the Development of Wild-type Transthyretin Amyloid Cardiomyopathy

Completed Last updated 9 April 2026
What this trial tests

trial testing Interview in Amyloid Cardiomyopathy in 180 participants. Completed in 20 November 2025.

Timeline
16 February 2024
Primary endpoint
20 November 2025
20 November 2025

Quick facts

Lead sponsorMedical University of Graz
StatusCompleted
Study typeOBSERVATIONAL
Enrollment180
Start date16 February 2024
Primary completion20 November 2025
Estimated completion20 November 2025
Sites1 location across Austria

Drugs / interventions tested

Conditions studied

Sponsor

Medical University of Graz

Who can join

60 and older, any sex, with Amyloid Cardiomyopathy or Wild Type ATTR Amyloidosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to investigate the association between increased lifetime physical activity and the development of wild-type transthyretin amyloid cardiomyopathy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Interview

Trials testing the same drug.

Other recruiting trials for Amyloid Cardiomyopathy

Currently open trials in the same condition.

Other Medical University of Graz trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06261216.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing